Vektor Medical Bolsters Team to Accelerate Roll-Out of Computationally-Intelligent Technology
Arrhythmia innovator appoints strategic, AI and product executives as it ramps up commercial expansion
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical, developer of the world’s first technology to rapidly map arrhythmias anywhere in the heart using only 12-lead ECG data, today announced the appointment of three key executives. The appointments, which come as Vektor prepares to expand the commercial availability of its vMap technology in the U.S., are Joe Braidwood as Chief Strategy Officer, Christian David Márton, Ph.D., as Vice President of Technology and Averee Chang as Vice President of Product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005483/en/
Joe Braidwood, Chief Strategy Officer (Photo: Business Wire)
“Through its early commercial success, we've seen that vMap has the potential to transform arrhythmia care," said Rob Krummen, CEO. "Joe, Averee and Christian are leaders in their respective fields, with distinct perspectives that will help drive our vision forward. I’m thrilled to welcome them to the team and look forward to working closely together through this exciting phase of our journey."
Joe Braidwood is a seasoned commercial leader with over 15 years of experience leading startups across the artificial intelligence (AI), consumer technology, and healthcare industries. Most notably, he served as Chief Marketing Officer leading go-to market strategy for the British AI technology startup SwiftKey, which was acquired by Microsoft in 2016 for $250 million. As Chief Strategy Officer for Vektor, he will lead the company’s strategic partnerships and business development. Joe earned his M.A. in Law from the University of Cambridge and completed an M.P.A. fellowship at Brown University.
Christian David Márton, Ph.D., has extensive experience as a machine learning-focused biomedical engineer and researcher. Most recently he was an AI research scientist at the Icahn School of Medicine & the Friedman Brain Institute at Mount Sinai, where he modeled biological data (brain rhythms) with artificial neural networks and built brain-inspired machine learning algorithms. As Vice President of Technology for Vektor, he will leverage machine learning in conjunction with tools from across a variety of different disciplines to derive insights into complex arrhythmias. He earned his Ph.D. in Bioengineering from Imperial College London and his B.A. from Princeton University, and conducted research at the Max-Planck Institute, the Princeton Neuroscience Institute, and the National Institutes of Health (NIH).
Averee Chang has nearly a decade of experience in new product and a focus on software, quality, validation, and research. She has held a variety of roles at Vektor with increasing levels of responsibility. Most recently, Averee was Director of Product Development and spearheaded vMap’s FDA clearance. She will continue to oversee the vMap product in her new role as Vice President of Product. She earned her B.S. in Bioengineering from the University of California, Berkeley.
vMap is designed to quickly, easily, and non-invasively map arrhythmia sources associated with focal- or fibrillation- type arrhythmias in all four chambers of the heart, the septal wall, and the outflow tracts. The easy-to-use system takes less than three minutes for a clinician to input case information, upload and markup an ECG, and receive a 3D interactive arrhythmia source location map visualizing the inside and outside of the heart.
About Vektor Medical
San Diego-based Vektor Medical, Inc. is the developer of the world’s first technology to rapidly map arrhythmias anywhere in the heart using only 12-lead ECG data. This data is analyzed using proprietary computational modeling to create actionable 2D information and 3D cardiac hot spots for the whole heart. The company’s smart, simple, and non-invasive cardiac arrhythmia mapping platform aims to improve first-pass ablation success, lower risks from invasive mapping and long fluoro exposure, and reduce procedure times, all of which are expected to reduce healthcare costs associated with ablation.
Source: Vektor Medical, Inc.